What To Know About RBC Capital's Downgrade of Sangamo Therapeutics

RBC Capital downgraded its rating of Sangamo Therapeutics SGMO to Sector Perform with a price target of $2.00, changing its price target from $6.00 to $2.00.

Shares of Sangamo Therapeutics are trading up 0.0% over the last 24 hours, at $0.46 per share.

A move to $2.00 would account for a 334.78% increase from the current share price.

About Sangamo Therapeutics

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.